These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 12480308)
1. Applying peptide antigens onto bare skin: induction of humoral and cellular immune responses and potential for vaccination. Partidos CD; Beignon AS; Brown F; Kramer E; Briand JP; Muller S J Control Release; 2002 Dec; 85(1-3):27-34. PubMed ID: 12480308 [TBL] [Abstract][Full Text] [Related]
2. Modulation of immune responses with transcutaneously deliverable adjuvants. Partidos CD; Beignon AS; Briand JP; Muller S Vaccine; 2004 Jun; 22(19):2385-90. PubMed ID: 15193399 [TBL] [Abstract][Full Text] [Related]
3. Immunity under the skin: potential application for topical delivery of vaccines. Partidos CD; Beignon AS; Mawas F; Belliard G; Briand JP; Muller S Vaccine; 2003 Jan; 21(7-8):776-80. PubMed ID: 12531358 [TBL] [Abstract][Full Text] [Related]
10. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441 [TBL] [Abstract][Full Text] [Related]
11. Mucosal delivery of vaccine antigens and its advantages in pediatrics. De Magistris MT Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335 [TBL] [Abstract][Full Text] [Related]
12. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. Babiuk S; Baca-Estrada M; Babiuk LA; Ewen C; Foldvari M J Control Release; 2000 May; 66(2-3):199-214. PubMed ID: 10742580 [TBL] [Abstract][Full Text] [Related]
14. ISCOMATRIX adjuvant for antigen delivery. Pearse MJ; Drane D Adv Drug Deliv Rev; 2005 Jan; 57(3):465-74. PubMed ID: 15560952 [TBL] [Abstract][Full Text] [Related]
15. Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in mice. Grenfell RF; Shollenberger LM; Samli EF; Harn DA Clin Vaccine Immunol; 2015 Mar; 22(3):336-43. PubMed ID: 25609075 [TBL] [Abstract][Full Text] [Related]
16. The bare skin and the nose as non-invasive routes for administering peptide vaccines. Partidos CD; Beignon AS; Semetey V; Briand JP; Muller S Vaccine; 2001 Mar; 19(17-19):2708-15. PubMed ID: 11257413 [TBL] [Abstract][Full Text] [Related]
17. Vesicular carrier constructs for topical immunisation. Vyas SP; Khatri K; Mishra V Expert Opin Drug Deliv; 2007 Jul; 4(4):341-8. PubMed ID: 17683248 [TBL] [Abstract][Full Text] [Related]
18. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Jackson DC; Purcell AW; Fitzmaurice CJ; Zeng W; Hart DN Curr Drug Targets; 2002 Apr; 3(2):175-96. PubMed ID: 11958299 [TBL] [Abstract][Full Text] [Related]
19. Initiation of adaptive immune responses by transcutaneous immunization. Warger T; Schild H; Rechtsteiner G Immunol Lett; 2007 Mar; 109(1):13-20. PubMed ID: 17320194 [TBL] [Abstract][Full Text] [Related]
20. Decision-making at the surface of the intact or barrier disrupted skin: potential applications for vaccination or therapy. Partidos CD; Muller S Cell Mol Life Sci; 2005 Jul; 62(13):1418-24. PubMed ID: 15818468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]